Trials of Adjuvant Chemotherapy for Operable Breast Cancer

[1]  Stephen E. Jones,et al.  Adjuvant Therapy of Cancer , 1990 .

[2]  M. Baum,et al.  Is there a role for perioperative adjuvant therapy in the treatment of early breast cancer? , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  M. Baum,et al.  RETROVIRUSES IN MONOCYTES FROM PATIENTS WITH BREAST CANCER , 1988, The Lancet.

[4]  N. Richardson.  Singing the Praises of Apollo , 1988, The Classical Review.

[5]  W. McGuire,et al.  DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens , 1988, Cancer.

[6]  S. Leinster,et al.  PARTICLES WITH PROPERTIES OF RETROVIRUSES IN MONOCYTES FROM PATIENTS WITH BREAST CANCER , 1988, The Lancet.

[7]  M. Retsky,et al.  Prospective computerized simulation of breast cancer: comparison of computer predictions with nine sets of biological and clinical data. , 1987, Cancer research.

[8]  R. Gelber,et al.  Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. , 1987, Cancer research.

[9]  A. Eggermont,et al.  Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. , 1987, Surgery.

[10]  I. Henderson,et al.  Adjuvant systemic therapy for early breast cancer. , 1987, Current problems in cancer.

[11]  R. Gelber,et al.  Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis , 1986, Cancer.

[12]  R. Gelber,et al.  A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Gelber,et al.  The concept of an overview of cancer clinical trials with special emphasis on early breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Goldhirsch,et al.  Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. , 1985, Human pathology.

[15]  N Gunduz,et al.  Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. , 1983, Cancer research.

[16]  R. Hiramoto,et al.  Surgical adjuvant chemotherapy of metastatic murine osteosarcoma , 1980, International journal of cancer.

[17]  N Gunduz,et al.  Effect of surgical removal on the growth and kinetics of residual tumor. , 1979, Cancer research.

[18]  S. Garattini,et al.  In vitro uptake and cytotoxicity of adriamycin in primary and metastatic Lewis lung carcinoma. , 1979, European journal of cancer.

[19]  A. Di Marco,et al.  Combination chemotherapy and surgical adjuvant chemotherapy on MS-2 sarcoma and lung metastases in mice. , 1979, European journal of cancer.

[20]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[21]  R. Nissen-Meyer,et al.  Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer , 1978, Cancer.

[22]  J. Venditti,et al.  Effectiveness of clinically active antineoplastic drugs in a surgical‐adjuvant chemotherapy treatment regimen using the lewis lung (LL) carcinoma , 1978, International journal of cancer.

[23]  S. Garattini,et al.  Differential distribution of antitumor agents in primary and secondary tumors. , 1977, Cancer treatment reports.

[24]  B. Jaffe,et al.  INHIBITION OF TUMOR GROWTH IN VIVO AND IN VITRO BY PROSTAGLANDIN E , 1977 .

[25]  L Simpson-Herren,et al.  Effects of surgery on the cell kinetics of residual tumor. , 1976, Cancer treatment reports.

[26]  B. Jaffe,et al.  Inhibition of tumour growth in vivo and in vitro by prostaglandin E , 1976, Nature.

[27]  R. Stolfi,et al.  Rationale of combined modality therapy for cancer. , 1974, Cancer chemotherapy reports. Part 2.

[28]  F. Schabel,et al.  Success and failure in the treatment of solid tumors. 3. "Cure" of metastatic Lewis lung carcinoma with methyl-CCNU (NSC-95442) and surgery-chemotherapy. , 1972, Cancer chemotherapy reports.

[29]  W. Dewys.  Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. , 1972, Cancer research.

[30]  S. R. Humphreys,et al.  Relationship of dose schedules to the effectiveness of adjuvant chemotherapy. , 1970, Cancer chemotherapy reports.

[31]  D. Martin,et al.  Enhanced cures of spontaneous murine mammary carcinomas with surgery and five-compound combination chemotherapy, and their immunotherapeutic interrelationship. , 1970, Cancer research.

[32]  D. Martin,et al.  Enhanced cures of spontaneous murine mammary tumors with surgery, combination chemotherapy, and immunotherapy. , 1970, Cancer research.

[33]  H. H. Lloyd,et al.  Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma 755. , 1969, Cancer chemotherapy reports.

[34]  I. Tannock,et al.  Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. , 1969, Journal of the National Cancer Institute.

[35]  H. Skipper,et al.  Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. , 1968, Cancer chemotherapy reports.

[36]  A. Goldin,et al.  An experimental model for studying factors which influence metastasis of malignant tumors , 1967, International journal of cancer.

[37]  W. Wilcox.  The last surviving cancer cell: The chances of killing it , 1966, Cancer chemotherapy reports.

[38]  D. Martin,et al.  COMBINATION THERAPY WITH CYCLOPHOSPHAMIDE AND ZYMOSAN ON A SPONTANEOUS MAMMARY CANCER IN MICE. , 1964, Cancer research.

[39]  Daniel S. Martin,et al.  Surgery, Cancer Chemotherapy, Host Defenses, and Tumor Size , 1962 .

[40]  A. Goldin,et al.  Evaluation of surgery and chemotherapy in the treatment of mouse mammary adenocarcinoma 755. , 1962, Cancer chemotherapy reports.

[41]  D. S. Martin.  Cancer treatment: immunologic and chemotherapeutic interrelationships. , 1961, JAMA.

[42]  H. Greene,et al.  The inhibitory influence of a transplanted hamster lymphoma on metastasis. , 1960, Cancer research.

[43]  N. Mantel,et al.  The effect of removal of a "primary" tumor on the development of spontaneous metastases. I. Development of a standardized experimental technic. , 1959, Cancer research.

[44]  D. S. Martin.  An appraisal of chemotherapy as an adjuvant to surgery for cancer. , 1959, American journal of surgery.

[45]  W. Schatten.  An experimental study of postoperative tumor metastases. I. Growth of pulmonary metastases following total removal of primary leg tumor , 1958, Cancer.

[46]  R. Fugmann,et al.  A role for chemotherapy as an adjunct to surgery. , 1957, Cancer research.

[47]  Edwin Silverberg,et al.  Cancer statistics, 1988 , 1988, CA: a cancer journal for clinicians.

[48]  S. Carter.  Selection bias in clinical trials. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Holland,et al.  Surgical adjuvant chemotherapy. , 1977, Annual review of medicine.

[50]  M. Straus,et al.  The effect of surgery and pretreatment or posttreatment adjuvant chemotherapy on primary tumor growth in an animal model , 1975 .

[51]  N. Berlin.  Research Strategy in Cancer: Screening, Diagnosis, Prognosis , 1975 .

[52]  Frei E rd.  A commentary. Selected considerations regarding chemotherapy as adjuvant in cancer treatment. , 1966, Cancer chemotherapy reports.

[53]  D. S. Martin.  CHEMOTHERAPEUTIC CURE OF SPONTANEOUS MOUSE CANCER. , 1964, Acta - Unio Internationalis Contra Cancrum.

[54]  R. Fugmann,et al.  Clinical implications of the interrelationship of tumor size and chemotherapeutic response. , 1960, Annals of surgery.